At present, only rhTPO and rhIL-11 have been approved by the NMPA to treat cancer treatment-induced thrombocytopenia (CTIT) in mainland China, but many studies have confirmed the efficiency and safety of TPO-RA drugs in non-hematologic malignancies. The gene discussed is TPO; the disease is hematologic disorder.